Business Context and Reporting Period
This Form 8-K is filed by Salarius Pharmaceuticals, Inc. (not Decoy Therapeutics Inc.) on September 16, 2021, reporting an event that occurred on September 15, 2021. The filing addresses the company's compliance status with Nasdaq listing requirements.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the stock price performance required for listing compliance.
Material Changes
The primary material change is the resolution of a listing deficiency. The Nasdaq Listing Qualifications Department confirmed that the closing bid price of the Company's common stock was at or above $1.00 per share for 10 consecutive business days (August 31 to September 14, 2021). Consequently, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2).
Guidance, Outlook, and Risks
The filing indicates that the matter regarding the stock price deficiency is now closed. No forward-looking guidance, management commentary on operations, or discussion of new risks or contingencies is provided in this document.
Investor Verification Checklist
- Verify the registrant name is Salarius Pharmaceuticals, Inc. (SLRX), not Decoy Therapeutics Inc.
- Confirm the stock price has remained above $1.00 to maintain Nasdaq compliance.
- Review subsequent filings for any new listing notices or financial updates.